- Gastroenterology Education and CPD for trainees and specialists - https://www.gastrotraining.com -
Gastro Oesophageal Reflux Disease (GORD)
What is GORD?
GORD is a condition that develops when the reflux of gastric content causes troublesome symptoms or complications. Heartburn and regurgitation are the characteristic symptoms of GORD. Heartburn is defined as a burning sensation in the retrosternal area. Regurgitation is defined as the perception of flow of refluxed gastric contents into the mouth or hypopharynx.GORD can also cause episodes of chest pain that resemble ischemic cardiac pain, without accompanying heartburn or regurgitation. Epigastric pain can also be the major symptom of GERD
GORD symptoms may occur when upright or supine or both. Symptoms occurring when supine may cause sleep disturbance. Physical exercise may induce troublesome symptoms of GERD in patients who have no/minimal symptoms at other times (exercise-induced gastroesophageal reflux)
Discuss the mechanism of GORD?
Discuss the diagnosis of GORD?
The typical reflux syndrome can be diagnosed on the basis of the characteristic symptoms, without diagnostic testing.
What are the complications of GORD?
Reflux oesophagitis, haemorrhage, stricture, Barrett’s oesophagus, and adenocarcinoma.
There is no increased risk of Barrett’s or oesophageal cancer with non erosive reflux disease. However 10-15% of NERD progress to erosive disease in US and Europe.
What is the role of endoscopy?
Endoscopy is a poor diagnostic test. Most patients (>50%) with GORD have no visible evidence of oesophagitis at endoscopy, making endoscopic appearance a poor guide to diagnosis and management of GORD. Further, the correlation between endoscopy findings and symptom severity is poor.
Endoscopy may be requested in patients with:
Discuss the endoscopic grading for severity of oesophagitis?
The severity of erosive oesophagitis on endoscopy is usually graded using the Los Angeles classification:
Grade A- One or more mucosal breaks no longer than 5 mm, none of which extends between the tops of the mucosal folds
Grade B- One or more mucosal breaks more than 5 mm long, none of which extends between the tops of two mucosal folds
Grade C- Mucosal breaks that extend between the tops of two or more mucosal folds, but which involve less than 75% of the oesophageal circumference
Grade D-Mucosal breaks which involve at least 75% of the oesophageal circumference
What is the role of pH monitoring?
Indicated primarily for the investigation of atypical or persistent symptoms despite appropriate therapy
Discuss the management of GORD?
How long to continue the PPI?
The PPI may be discontinued after a period of 4-8 weeks to confirm the need for ongoing therapy. However, the risk of recurrent endoscopic erosions is extremely high without maintenance therapy. Thus long term therapy is recommended for erosive oesophagitis with the aim of preventing recurrent oesophageal injury, in addition to complications such as stricture, haemorrhage, ulceration or Barrett’s epithelium. Currently there is no evidence that PPI therapy prevents the development or progression of Barrett’s epithelium.
Long term maintenance therapy is given at the lowest dose and frequency that is sufficient to achieve optimal control of the patient’s symptoms. Half dose PPI therapy is sufficient to maintain endoscopic remission in about 35% to 95% of patients with erosive oesophagitis. On demand therapy may also be acceptable because oesophagitis recurrence, in the absence of symptoms, occurs in fewer than 9% of patients
What is the role of supplementary night time H2RA therapy?
Supplementary nighttime H2RA therapy is not generally recommended for individuals who have responded incompletely or have failed to respond to standard dose or double dose PPI therapy of adequate duration.
Discuss H. Pylori and GORD?
H. Pylori testing is not necessary before starting treatment for typical symptoms of GORD. Further, it is not necessary to test routinely for H Pylori in a patient taking long term PPI therapy for GORD symptoms.
Eradication of H. Pylori has no clinically relevant adverse effect on the long term outcome of GORD
Background to this debate- There were concerns that the progression of H. pylori gastritis to metaplasia and gastric carcinoma might be hastened by long term PPI therapy for GORD. There is no evidence that PPI is an additional risk factor or that H. Pylori eradication affects the risk of gastric cancer in presence of PPI therapy.
In addition, eradication does not alter the therapeutic dose of PPI or cause an increase in reflux symptoms
What are the indications for antireflux surgery?
Limitations of surgery
Relapse needing repeat surgery
PPI may be needed after a period
Absence of documented benefit in preventing Barrett’s oesophagus
Prerequisites before surgery
Typical reflux symptoms and erosive oesophagitis on endoscopy or evidence of reflux on pH study
Discuss the extra oesophageal manifestations of GORD?
There is a significant association between GORD and cough, laryngitis, asthma, and dental erosions. Important features:
It is unclear whether gastroesophageal reflux is a significant causal or exacerbating factor in the pathogenesis of sinusitis, pulmonary fibrosis, pharyngitis, or recurrent otitis media
It is unclear whether gastroesophageal reflux plays a role in triggering apnoeic episodes in patients with obstructive sleep apnoea
Discuss the approach to a patient with GORD and non response to twice daily PPI?
Step 1- Check compliance. Exclude contributory causes like alendronate, NSAIDS, KCL, doxycycline etc
Step 2- Consider other diagnoses:
Ref
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com